Back to search

Harokopio University

Κλινική μελέτη φάσης ΙΙ διατροφικού συμπληρώματος σε ασθενείς με ΙΦΝΕ

Abstract

dc:description

Inflammatory Bowel Disease (IBD) affects 100/100,000 persons worldwide. Since current medical treatments have serious side effects, there is a research interest in natural supplements that could serve as potential non-pharmacological treatments. As such, Mastiha, a natural product, with high content in antioxidant and anti-inflammatory phytochemicals, mainly terpenes, is under investigation.The aim of the present Doctoral Dissertation was: a) to investigate the absorption and bioavailability of Mastiha’s terpenes in healthy humans, b) To evaluate the effects of Mastiha on the clinical course of IBD adjunct to medical treatment.To evaluate the bioavailability of Mastiha’s terpenes, seventeen healthy male volunteers followed a low-phytochemical diet for 5 days. After overnight fasting, volunteers consumed Mastiha powder and blood samples were collected on time-points 0h (before ingestion) and 0.5h, 1h, 2h, 4h, 6h, 24h (post- ingestion). UHPLC-HRMS was applied for high throughput analysis of plasma. Serum resistance to oxidation, oxidized LDL levels (oxLDL) and uric acid levels were measured. Plasma free amino acids (AAs) were identified and quantified with GC-MS analysis.UHPLC-HRMS/MS analysis showed that major terpenes were bioavailable since 0.5h, reaching a peak between 2h and 4h. Serum resistance to oxidation reached statistical significance at 4h, peaked at 6h and remained significant until 24h. oxLDL levels were reduced significantly from time point-1h until time point-6h. Additionally, It was shown that plasma free AAs are modulated in response to terpenes intake. To evaluate the effects of Mastiha administration on active IBD, a Phase-II randomised, double-blind, placebo-controlled clinical trial was designed. Α total of 60 IBD patients were randomly allocated to Mastiha (2.8g/day) or placebo groups for 3 months adjunct to stable medical treatment. Medical and dietary history, Inflammatory Bowel Disease Questionnaire (IBDQ), disease activity, biochemical indices, oxidative stress, plasma free AAs, faecal and blood inflammatory markers were assessed. A clinically important difference between groups in IBDQ was the primary outcome. The results showed a significant improvement in IBDQ in verum compared with baseline. There was a significant decrease in faecal lysozyme in Mastiha patients with the mean change being significant and significant increases of faecal lactoferrin and calprotectin in placebo group. Additionally, oxLDL was significantly decreased in Mastiha arm and the ratios of oxLDL/HDL and oxLDL/LDL were significantly decreased in the same group with the mean changes being significantly different. Similarly, to evaluate the effects of Mastiha administration on inactive IBD, a total of 68 patients were randomly allocated to Mastiha (2.8g/day) or placebo adjunct to stable medication. Primary endpoint was clinical relapse rate at 6 months. Although Mastiha was not proven superior to placebo in remission rate, attenuation in increase of free AAs levels in verum group was reported. Serum IL-6, faecal calprotectin and faecal lactoferrin increased only in placebo group. In conclusion, this Thesis showed that Mastiha’s major terpenes are bioavailable and are potential mediators of antioxidant defence in vivo. Regulation of faecal lysozyme in active IBD was shown pointing towards a prebiotic effect. Last, since Mastiha inhibited an increase in plasma free AAs seen in quiescent IBD and change of AAs is considered an early prognostic marker of disease activity, this indicates a potential role of Mastiha in remission maintenance.

Degree

thesis:*
Grantor dc:publisher
Harokopio University
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papada, Efstathia
  • Παπαδά, Ευσταθία

Subjects

dc:subject × 14

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44475

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papada, Efstathia; Παπαδά, Ευσταθία. Κλινική μελέτη φάσης ΙΙ διατροφικού συμπληρώματος σε ασθενείς με ΙΦΝΕ. Harokopio University, 2018. http://hdl.handle.net/10442/hedi/44475